Keytruda® (pembrolizumab) – New indication
April 22, 2019 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with Inlyta® (axitinib), for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Download PDF
